NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies Journal Article

   

Authors:	Alyea, E. P.; DeAngelo, D. J.; Moldrem, J.; Pagel, J. M.; Przepiorka, D.; Sadelain, M.; Young, J. W.; Giralt, S.; Bishop, M.; Riddell, S.
Article Title:	NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies
Abstract:	Prevention of relapse after allogeneic hematopoietic stem cell transplantation is the most likely approach to improve survival of patients treated for hematologic malignancies. Herein we review the limits of currently available transplant therapies and the innovative strategies being developed to overcome resistance to therapy or to fill therapeutic modalities not currently available. These novel strategies include nonimmunologic therapies, such as targeted preparative regimens and posttransplant drug therapy, as well as immunologic interventions, including graft engineering, donor lymphocyte infusions, T cell engineering, vaccination, and dendritic cell-based approaches. Several aspects of the biology of the malignant cells as well as the host have been identified that obviate success of even these newer strategies. To maximize the potential for success, we recommend pursuing research to develop additional targeted therapies to be used in the preparative regimen or as maintenance posttransplant, better characterize the T cell and dendritic cells subsets involved in graft-versus-host disease and the graft-versus-leukemia/tumor effect, identify strategies for timing immunologic or nonimmunologic therapies to eliminate the noncycling cancer stem cell, identify more targets for immunotherapies, develop new vaccines that will not be limited by HLA, and develop methods to identify populations at very high risk for relapse to accelerate clinical development and avoid toxicity in patients not at risk for relapse. © 2010 American Society for Blood and Marrow Transplantation.
Keywords:	disease-free survival; transplantation, homologous; unclassified drug; acute granulocytic leukemia; busulfan; lenalidomide; thalidomide; clinical trial; review; cancer combination chemotherapy; monotherapy; nonhuman; radiation dose; cytarabine; rituximab; drug megadose; t lymphocyte; cell survival; imatinib; interleukin 2; multiple cycle treatment; multiple myeloma; cell maturation; dendritic cell; granulocyte macrophage colony stimulating factor; relapse; recurrence; cyclophosphamide; hematopoietic stem cell transplantation; chronic myeloid leukemia; gene transfer; cd20 antigen; t lymphocyte receptor; antigen presentation; hematologic malignancy; whole body radiation; hematologic neoplasms; dna modification; immunotherapy; cancer vaccine; tissue distribution; graft versus host reaction; transplantation conditioning; donor lymphocyte infusion; allogeneic hematopoietic stem cell transplantation; natural killer cell; 5 aza 2' deoxycytidine; lymphoproliferative disease; wt1 protein; t cell depletion; major histocompatibility complex; leukemia relapse; graft vs host disease; chronic lymphatic leukemia; cell activation; obatoclax; graft versus leukemia effect; cell expansion; alemtuzumab; lymphocytoma; hla system; carbonate dehydratase; allogeneic hematopoietic cell transplantation; acute graft-versus-host disease; relapse prevention; resistant leukemia; 4 [4 [2 (4 chlorophenyl) 5,5 dimethyl 1 cyclohexen 1 ylmethyl] 1 piperazinyl] n [4 [3 morpholino 1 (phenylthiomethyl)propylamino] 3 (trifluoromethylsulfonyl)benzenesulfonyl]benzamide; leukemia antigen; pamidronic acid; pr1 antigen
Journal Title:	Biology of Blood and Marrow Transplantation
Volume:	16
Issue:	8
ISSN:	1083-8791
Publisher:	Elsevier Inc.
Date Published:	2010-08-01
Start Page:	1037
End Page:	1069
Language:	English
DOI:	10.1016/j.bbmt.2010.05.005
PUBMED:	20580849
PROVIDER:	scopus
PMCID:	PMC3235046
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-77954288771&partnerID=40&md5=6c66bc8c1209dd1988209fe83e93e53d
Notes:	--- - "Cited By (since 1996): 4" - "Export Date: 20 April 2011" - "CODEN: BBMTF" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/3600